Abstract
Acute hepatitis remains a significant pediatric health concern, particularly in developing countries like India. While viral hepatitis, especially Hepatitis A, is the primary cause, other factors such as mixed infections (e.g., enteric fever) also contribute to the clinical burden. This study examines the clinical spectrum of acute hepatitis in 68 children, focusing on identifying prognostic markers for Acute Liver Failure (ALF). The findings reveal that Hepatitis A is the dominant etiology and that liver enzyme levels in the second week of illness—specifically SGOT and SGPT exceeding 2000 U/L—serve as critical predictors for ALF development. Despite a 26% ALF incidence rate, early recognition and monitoring led to a 100% survival rate in this cohort.
Introduction
Acute hepatitis in the pediatric population presents a varied clinical spectrum, often characterized by fever and icterus. In regions like India, the feco-oral route facilitates the spread of Hepatitis A, which remains the most common trigger. However, clinicians must also remain vigilant for atypical presentations and co-infections, such as enteric fever, which can complicate the clinical course. A major challenge in managing these patients is the early identification of those at risk for Acute Liver Failure (ALF), a life-threatening complication. This research explores the potential of routine laboratory parameters, such as liver enzymes, to act as prognostic markers, enabling better clinical monitoring and timely intervention.
Methods
This prospective observational study was conducted at the Base Hospital in Delhi, India. The study enrolled 68 children aged 1 to 15 years who presented with acute onset jaundice (within 7 days of symptom onset). To ensure the findings were specific to acute infection, children with pre-existing chronic liver disease or significant comorbidities were excluded.
ALF was defined according to standard pediatric criteria: hepatic-based coagulopathy (PT > 15s or INR > 1.5) with clinical encephalopathy, or severe coagulopathy (PT > 20s or INR > 2) regardless of encephalopathy. Data collection included detailed epidemiological history and longitudinal laboratory monitoring of liver function tests (LFTs) and prothrombin time (PT/INR) over a three-week period. Statistical analysis was performed using SPSS (v21), employing Chi-square tests and Student’s t-tests with a significance level of p < 0.05.
Results and Demographics
The study cohort consisted of 68 patients, with a notable male predominance (78%). The age distribution showed that nearly half of the cases (49%) occurred in children between 6 and 10 years of age.
Etiological testing confirmed that 100% of the patients were positive for Hepatitis A IgM antibodies. Interestingly, 8.8% of these cases also tested positive for enteric fever, indicating a significant rate of co-infection. Regarding outcomes, 26% of the participants (18 children) developed features of ALF. However, with intensive monitoring and supportive care, all patients survived.
Key Insights: Clinical Presentation and Prognostic Markers
A striking finding of this study was the universal presence of abdominal pain among the participants, a higher prevalence than typically reported in existing literature.
Beyond clinical symptoms, the study identified a critical "predictive window" in the second week of illness. While serum bilirubin levels remained relatively stable throughout the three-week observation period, liver enzymes (SGOT and SGPT) showed a declining trend. Crucially, the enzyme values recorded during the second week were strongly associated with the development of ALF. Specifically, enzyme levels exceeding 2000 U/L during this period were highly predictive of progression to liver failure (p < 0.0001).
Conclusion
Hepatitis A continues to be the leading cause of acute hepatitis in children in this demographic, with a significant proportion of patients progressing to ALF. This study underscores the importance of regular monitoring of liver enzymes, particularly during the second week of illness, as a reliable prognostic tool. Identifying high-risk patients through these biochemical markers allows for intensified monitoring and early referral for specialized care, such as liver transplantation, if necessary. While the study is limited by its sample size and single-center design, it provides a clear clinical threshold for risk stratification in pediatric acute hepatitis.
Summary updated